ArticleBlood advances2024
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- Article
- Clinical implications of minimal residual disease monitoring in multiple myeloma.International journal of hematology · 2026Review
- Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma.Cancer research communications · 2026Article
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.Frontiers in oncology · 2026Article
- EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.Annals of hematology · 2025Review
- Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.Blood cancer discovery · 2025Review
- Peripheral blood tRNA-derived fragments as novel noninvasive biomarkers for diagnosis and prognostic stratification in multiple myeloma.Frontiers in immunology · 2025Article
- Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences.Mediterranean journal of hematology and infectious diseases · 2025Review
- Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.American journal of hematology · 2025Article
- Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.